Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1101 | DOI: 10.1530/endoabs.49.EP1101

Selcuk University, konya, Turkey.


Aim: Thirty female Wistar albino rats with surgically endometriotic implants were randomly randomized into three treatment groups: oral rosuvastatin (20 mg kg per day; oral rosuvastatin group 1; n=10), oral progesterone (Dienogest group 2; n=10), and intraperitoneal bevacizumab (2.5 mg/kg of single intaperitoneal injection of bevacizumab; group 3; n=10) respectively, for 10 day and post-treatment variables were compared.

Results: The endometrium foci as were measured on days 1 and 10. Rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than progesterone group (both, P<0.017; respectively). The median glandular epithelium and uterine vessels and histopathological scores values did not show statistically significant difference among group 1 and group 3 (P>0.017). No significant different reduction was observed in between the three groups for the myometrium, endometrial stroma, in histopathological scores (P>0.017). Endometrial thickness and uterine volume values analyzed in all treatment groups. Endometrial thickness values and uterine volume values was more significantly reduced in the oral rosuvastatin medication than oral progesterone group (both, P<0.017; respectively). Moreover, endometrial thickness and uterine volume values were not different in groups I compared with group 3 (P>0.017).

Conclusion: In conclusion, rosuvastatin and intaperitoneal injection of bevacizumab may causes more significant regression of surgically endometriotic implants in rats than oral progesterone medications.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.